中华临床医师杂志（电子版）
中華臨床醫師雜誌（電子版）
중화림상의사잡지（전자판）
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2014年
5期
902-905
,共4页
贾慧%霍丽娟%张婕%王晋江%武淑君
賈慧%霍麗娟%張婕%王晉江%武淑君
가혜%곽려연%장첩%왕진강%무숙군
血管紧张素转换酶抑制药%血管紧张素Ⅱ1型受体拮抗剂%肝硬化%转化生长因子β1%Smad3蛋白质
血管緊張素轉換酶抑製藥%血管緊張素Ⅱ1型受體拮抗劑%肝硬化%轉化生長因子β1%Smad3蛋白質
혈관긴장소전환매억제약%혈관긴장소Ⅱ1형수체길항제%간경화%전화생장인자β1%Smad3단백질
Angiotensin-converting enzyme inhibitors%Angiotensin II type 1 receptor blockers%Liver cirrhosis%Transforming growth factor beta1%Smad3 protein
目的：通过依那普利、缬沙坦对肝纤维化大鼠转化生长因子β1（TGFβ1）/Smad3及结缔组织生长因子（CTGF）表达的影响，探讨两药物对肝纤维化的治疗作用。方法制备四氯化碳诱导的肝纤维化大鼠模型，60 d造模成功后分别给予依那普利、缬沙坦灌胃15 d。对各组大鼠肝组织进行HE及Masson染色，Western blotting检测TGFβ1/Smad3、CTGF蛋白表达，Real-time PCR检测TGFβ1/Smad3及CTGF mRNA表达。结果依那普利、缬沙坦可明显减轻大鼠肝组织纤维化程度，TGFβ1/Smad3、CTGF蛋白（0.51±0.10、0.49±0.11 vs.0.60±0.09；0.72±0.09、0.69±0.07 vs.0.98±0.13；0.51±0.05、0.47±0.13 vs.0.61±0.05，P均＜0.05）及mRNA（2.77±0.83、2.97±0.48 vs.4.07±0.97；4.15±0.98、4.17±0.98 vs.6.06±0.85；5.82±1.21、5.34±1.24 vs.7.63±1.25，P均＜0.05）表达较模型组降低。结论依那普利、缬沙坦对大鼠肝纤维化具有抑制作用，为探索新的治疗药物提供了实验依据。
目的：通過依那普利、纈沙坦對肝纖維化大鼠轉化生長因子β1（TGFβ1）/Smad3及結締組織生長因子（CTGF）錶達的影響，探討兩藥物對肝纖維化的治療作用。方法製備四氯化碳誘導的肝纖維化大鼠模型，60 d造模成功後分彆給予依那普利、纈沙坦灌胃15 d。對各組大鼠肝組織進行HE及Masson染色，Western blotting檢測TGFβ1/Smad3、CTGF蛋白錶達，Real-time PCR檢測TGFβ1/Smad3及CTGF mRNA錶達。結果依那普利、纈沙坦可明顯減輕大鼠肝組織纖維化程度，TGFβ1/Smad3、CTGF蛋白（0.51±0.10、0.49±0.11 vs.0.60±0.09；0.72±0.09、0.69±0.07 vs.0.98±0.13；0.51±0.05、0.47±0.13 vs.0.61±0.05，P均＜0.05）及mRNA（2.77±0.83、2.97±0.48 vs.4.07±0.97；4.15±0.98、4.17±0.98 vs.6.06±0.85；5.82±1.21、5.34±1.24 vs.7.63±1.25，P均＜0.05）錶達較模型組降低。結論依那普利、纈沙坦對大鼠肝纖維化具有抑製作用，為探索新的治療藥物提供瞭實驗依據。
목적：통과의나보리、힐사탄대간섬유화대서전화생장인자β1（TGFβ1）/Smad3급결체조직생장인자（CTGF）표체적영향，탐토량약물대간섬유화적치료작용。방법제비사록화탄유도적간섬유화대서모형，60 d조모성공후분별급여의나보리、힐사탄관위15 d。대각조대서간조직진행HE급Masson염색，Western blotting검측TGFβ1/Smad3、CTGF단백표체，Real-time PCR검측TGFβ1/Smad3급CTGF mRNA표체。결과의나보리、힐사탄가명현감경대서간조직섬유화정도，TGFβ1/Smad3、CTGF단백（0.51±0.10、0.49±0.11 vs.0.60±0.09；0.72±0.09、0.69±0.07 vs.0.98±0.13；0.51±0.05、0.47±0.13 vs.0.61±0.05，P균＜0.05）급mRNA（2.77±0.83、2.97±0.48 vs.4.07±0.97；4.15±0.98、4.17±0.98 vs.6.06±0.85；5.82±1.21、5.34±1.24 vs.7.63±1.25，P균＜0.05）표체교모형조강저。결론의나보리、힐사탄대대서간섬유화구유억제작용，위탐색신적치료약물제공료실험의거。
Objective To investigate Enalapril and Valsartan on liver in experimental fibrotic rats, by observing its effects on the expressions of TGFβ1, Smad3 and CTGF. Methods A total of 52 male wistar rats were randomly divided into two groups:the control group (n=16), the model group (n=36). In the model group, all rats were given subcutaneous injections of 40%CCl4 once every three days. Rats in the control group were given subcutaneous injections of oil. When the hepatic fibrosis models success 60 days later, 20 rats selected randomly from the model group were given Enalapril or Valsartan until 75 days by gastric gavage. Histopathological study of the liver tissues was done with HE and Masson staining. Expression of TGFβ1, Smad3 and CTGF protein was detected by western blotting. The mRNA expressions of Smad3 and CTGF were examined by Real-time PCR. Results Enalapril and Valsartan attenuated the degree of hepatic fibrosis. TGFβ1 mRNA expression level (2.77±0.83, 2.97±0.48 vs. 4.07±0.97, P<0.05) and protein expression level (0.51±0.10, 0.49±0.11 vs. 0.60±0.09, P<0.05), Smad3 mRNA expression level (4.15±0.98, 4.17±0.98 vs. 6.06±0.85, P<0.05)and protein expression level (0.72±0.09, 0.69±0.07 vs. 0.98±0.13, P<0.05), CTGF mRNA expression level (5.82±1.21, 5.34±1.24 vs. 7.63±1.25, P<0.05) and protein expression level (0.51±0.05, 0.47±0.13 vs. 0.61±0.05, P<0.05) were reduced by Enalapril and Valsartan. Conclusion Enalapril and Valsartan can delay the progression of hepatic fibrosis.
